_____________________
                                                   |    OMB APPROVAL     |
                                                   |_____________________|
                                                   |OMB NUMBER: 	 | 
                    UNITED STATES                  |EXPIRES:             |
         SECURITIES AND EXCHANGE COMMISSION        |   JUNE 30, 2012	 |
               Washington, D.C.  20549             |ESTIMATED AVERAGE    |
                                                   |BURDEN HOURS         |
                                                   |PER RESPONSE ...11	 |
                 SCHEDULE 13G                       _____________________|



                    Under the Securities Exchange Act of 1934
                             (Amendment No. _ )*


                 	Tandem Diabetes Care, Inc. (TNDM)          
                  ---------------------------------------------
                                (Name of Issuer)


                                  Common Stock
                -------------------------------------------------
                         (Title of Class of Securities)


                             	   875372203
                ----------------------------------------------------
                                 (CUSIP Number)


                                December 31, 2017
 ------------------------------------------------------------------------------
             (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:

     [X]  Rule 13d-1(b)

     [ ]  Rule 13d-1(c)

     [ ]  Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, 
and for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall 
not be deemed to be "filed" for the purpose of Section 18 of the 
Securities Exchange Act of 1934 ("Act") or otherwise subject to 
the liabilities of that section of the Act but shall be subject 
to all other provisions of the Act (however, see the Notes).


------------------------------------------------------------------------------ 
CUSIP No.  875372203			SCHEDULE 13G
------------------------------------------------------------------------------
     (1)  NAMES OF REPORTING PERSONS
          I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only) 

          Alyeska Investment Group, L.P.

------------------------------------------------------------------------------
     (2)  CHECK THE APPROPRIATE BOX IF A MEMBER OF A  GROUP (See Instructions):
                                                            (a) [ ] 
                                                            (b) [ ]
------------------------------------------------------------------------------
     (3)  SEC USE ONLY

------------------------------------------------------------------------------
     (4)  CITIZENSHIP OR PLACE OF ORGANIZATION 

          Delaware
------------------------------------------------------------------------------
                                   (5) SOLE VOTING POWER
NUMBER OF				0
SHARES                             -------------------------------------------
BENEFICIALLY                       (6)  SHARED VOTING POWER
OWNED BY                                1,039,196
EACH REPORTING                     -------------------------------------------
PERSON WITH                        (7)  SOLE DISPOSITIVE POWER
					0
                                   -------------------------------------------
                                   (8)  SHARED DISPOSITIVE POWER 
                                        1,039,196   
------------------------------------------------------------------------------
    (9)   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 
         
           1,039,196 
------------------------------------------------------------------------------
   (10)   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
          (See Instructions)                                            [ ]
------------------------------------------------------------------------------
   (11)   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 
           9.4%*       
------------------------------------------------------------------------------
   (12)   TYPE OF REPORTING PERSON (See Instructions) 
           IA          
------------------------------------------------------------------------------
*The reporting persons are the beneficial owners of 1,039,195 shares of Common 
Stock of the Issuer, which constitutes approximately 9.43% of the Issuer's 
outstanding Common Stock shares. The percentage calculation assumes that there 
are currently 10,117,029 outstanding shares of Common Stock of the Issuer, 
based on the Issuer's Prospectus Supplement on Form 424(b)(5) filed with the 
Securities and Exchange Commission on October 13, 2017. 

------------------------------------------------------------------------------ 
CUSIP No.  875372203			SCHEDULE 13G
------------------------------------------------------------------------------
     (1)  NAMES OF REPORTING PERSONS
          I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only) 

          Alyeska Fund GP, LLC

------------------------------------------------------------------------------
     (2)  CHECK THE APPROPRIATE BOX IF A MEMBER OF A  GROUP (See Instructions):
                                                            (a) [ ] 
                                                            (b) [ ]
------------------------------------------------------------------------------
     (3)  SEC USE ONLY

------------------------------------------------------------------------------
     (4)  CITIZENSHIP OR PLACE OF ORGANIZATION 

          Delaware
------------------------------------------------------------------------------
                                   (5) SOLE VOTING POWER
NUMBER OF				0
SHARES                             -------------------------------------------
BENEFICIALLY                       (6)  SHARED VOTING POWER
OWNED BY                                1,039,196
EACH REPORTING                     -------------------------------------------
PERSON WITH                        (7)  SOLE DISPOSITIVE POWER
					0
                                   -------------------------------------------
                                   (8)  SHARED DISPOSITIVE POWER 
                                        1,039,196 
------------------------------------------------------------------------------
    (9)   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 
         
          1,039,196
------------------------------------------------------------------------------
   (10)   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
          (See Instructions)                                            [ ]
------------------------------------------------------------------------------
   (11)   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 
           9.4%*       
------------------------------------------------------------------------------
   (12)   TYPE OF REPORTING PERSON (See Instructions) 
           OO          
------------------------------------------------------------------------------
*The reporting persons are the beneficial owners of 1,039,195 shares of Common 
Stock of the Issuer, which constitutes approximately 9.43% of the Issuer's 
outstanding Common Stock shares. The percentage calculation assumes that there 
are currently 10,117,029 outstanding shares of Common Stock of the Issuer, 
based on the Issuer's Prospectus Supplement on Form 424(b)(5) filed with the 
Securities and Exchange Commission on October 13, 2017. 

------------------------------------------------------------------------------ 
CUSIP No.  875372203			SCHEDULE 13G
------------------------------------------------------------------------------
     (1)  NAMES OF REPORTING PERSONS
          I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only) 

          Alyeska Fund 2 GP, LLC

------------------------------------------------------------------------------
     (2)  CHECK THE APPROPRIATE BOX IF A MEMBER OF A  GROUP (See Instructions):
                                                            (a) [ ] 
                                                            (b) [ ]
------------------------------------------------------------------------------
     (3)  SEC USE ONLY

------------------------------------------------------------------------------
     (4)  CITIZENSHIP OR PLACE OF ORGANIZATION 

          Delaware
------------------------------------------------------------------------------
                                   (5) SOLE VOTING POWER
NUMBER OF				0
SHARES                             -------------------------------------------
BENEFICIALLY                       (6)  SHARED VOTING POWER
OWNED BY                              	1,039,196
EACH REPORTING                     -------------------------------------------
PERSON WITH                        (7)  SOLE DISPOSITIVE POWER
					0
                                   -------------------------------------------
                                   (8)  SHARED DISPOSITIVE POWER 
                                        1,039,196
------------------------------------------------------------------------------
    (9)   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 
         
          1,039,196
------------------------------------------------------------------------------
   (10)   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
          (See Instructions)                                            [ ]
------------------------------------------------------------------------------
   (11)   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 
           9.4%*       
------------------------------------------------------------------------------
   (12)   TYPE OF REPORTING PERSON (See Instructions) 
           OO          
------------------------------------------------------------------------------
*The reporting persons are the beneficial owners of 1,039,195 shares of Common 
Stock of the Issuer, which constitutes approximately 9.43% of the Issuer's 
outstanding Common Stock shares. The percentage calculation assumes that there 
are currently 10,117,029 outstanding shares of Common Stock of the Issuer, 
based on the Issuer's Prospectus Supplement on Form 424(b)(5) filed with the 
Securities and Exchange Commission on October 13, 2017.

------------------------------------------------------------------------------- 
CUSIP No. 875372203            	 SCHEDULE 13G
------------------------------------------------------------------------------
     (1)  NAMES OF REPORTING PERSONS
          I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only) 
	  Anand Parekh
          
------------------------------------------------------------------------------
     (2)  CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions): 
                                                           (a) [ ] 
                                                           (b) [ ]
------------------------------------------------------------------------------
     (3)  SEC USE ONLY

------------------------------------------------------------------------------
     (4)  CITIZENSHIP OR PLACE OF ORGANIZATION 
          United States of America
------------------------------------------------------------------------------
                                   (5) SOLE VOTING POWER
NUMBER OF				0
SHARES                             -------------------------------------------
BENEFICIALLY                       (6)  SHARED VOTING POWER
OWNED BY                                1,039,196
EACH REPORTING                     -------------------------------------------
PERSON WITH                        (7)  SOLE DISPOSITIVE POWER
					0
                                   -------------------------------------------
                                   (8)  SHARED DISPOSITIVE POWER 
                                        1,039,196
------------------------------------------------------------------------------
    (9)   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 

   	  1,039,196
------------------------------------------------------------------------------
   (10)   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
          (See Instructions)                                            [ ]
------------------------------------------------------------------------------
   (11)   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 
          9.4%*     
------------------------------------------------------------------------------
   (12)   TYPE OF REPORTING PERSON (See Instructions) 
          IN           
------------------------------------------------------------------------------
*The reporting persons are the beneficial owners of 1,039,195 shares of Common 
Stock of the Issuer, which constitutes approximately 9.43% of the Issuer's 
outstanding Common Stock shares. The percentage calculation assumes that there 
are currently 10,117,029 outstanding shares of Common Stock of the Issuer, 
based on the Issuer's Prospectus Supplement on Form 424(b)(5) filed with the 
Securities and Exchange Commission on October 13, 2017.



CUSIP NO.  875372203             SCHEDULE 13G


Item 1(a).      Name of Issuer:
		Tandem Diabetes Care, Inc.

               

Item 1(b).      Address of Issuer's Principal Executive Offices:
                11075 Roselle Street 
		San Diego, CA 92121



Item 2(a).      Name of Persons Filing:

	(i)	Alyeska Investment Group, L.P.

	(ii)	Alyeska Fund GP, LLC

	(iii)	Alyeska Fund 2 GP, LLC	

	(iv)	Anand Parekh




Item 2(b).      Address of Principal Business Office or, if None, Residence:


	(i)	77 West Wacker Drive, 7th Floor
              	Chicago, IL 60601
		
	(ii)	77 West Wacker Drive, 7th Floor
              	Chicago, IL 60601

	(iii)	77 West Wacker Drive, 7th Floor
              	Chicago, IL 60601

	(iv)	77 West Wacker Drive, 7th Floor
              	Chicago, IL 60601



Item 2(c).      Citizenship:

		(i)  	Alyeska Investment Group, L.P.- Delaware	

		(ii) 	Alyeska Fund GP, LLC- Delaware

		(iii) 	Alyeska Fund 2 GP, LLC- Delaware	

		(iv) 	Anand Parekh - United States of America	


	


Item 2(d).       Title of Class of Securities:
		 Common Stock
               

Item 2(e).      CUSIP Number:
		875372203
		
                 

Item 3.          If This Statement is Filed Pursuant to Sections 240.13d-1(b)
                 or 240.13d-2(b), Check Whether the Person Filing is a:

(a) Alyeska Investment Group, L.P., a limited partnership organized under the 
laws of the State of Delaware, is a registered investment adviser under Section 
203 of the Investment Advisers Act of 1940, as amended, and is reporting in 
accordance with 240.13d-1(b)(1)(ii)(E).

(b) Alyeska Fund GP, LLC, a limited liability company organized under the laws 
of the State of Delaware, serves as the General Partner and control person of 
Alyeska Master Fund, L.P., and is reporting in accordance with 
240.13d-1(b)(1)(ii)(G).

(c) Alyeska Fund 2 GP, LLC, a limited liability company organized under the laws
 of the State of Delaware, serves as the General Partner and control person of 
Alyeska Master Fund 2, L.P., and is reporting in accordance with 
240.13d-1(b)(1)(ii)(G).

(d) Anand Parekh is the Chief Executive Officer and control person of Alyeska 
Investment Group, L.P., and is reporting in accordance with 
240.13d-1(b)(1)(ii)(G).



Item 4.  Ownership.

Provide the following information regarding the aggregate number 
and percentage of the class of securities of the issuer identified 
in Item 1.

    (a) Amount beneficially owned: Please refer to items 5-9 of the cover 
	pages attached hereto

    (b) Percent of class: Please refer to item 11 of the cover pages attached 
	hereto

    (c)	Number of shares as to which the person has: Please refer to items 
	5-8 of the cover pages attached hereto

The reporting persons are the beneficial owners of 139,196 shares of Common 
Stock of the Issuer and hold warrants to purchase 900,000 shares of the 
Issuer's Common Stock (the "Warrants"), collectively constituting beneficial 
ownership of 1,039,195 shares of Common Stock of the Issuer.  The reporting 
persons are beneficial owners of  9.43% of the Issuer's outstanding Common 
Stock shares.  The percentage calculation assumes that there are currently 
10,117,029 outstanding shares of Common Stock of the Issuer, based on the 
Issuer's Prospectus Supplement on Form 424(b)(5) filed with the Securities 
and Exchange Commission on October 13, 2017 and assumes the exercise of the 
Warrants.

Item 5.  Ownership of Five Percent or Less of a Class.
	 Not Applicable


         
Item 6.  Ownership of More than Five Percent on Behalf of Another Person.
	 Not Applicable
	


Item 7.  Identification and Classification of the Subsidiary Which Acquired
         the Security Being Reported on By the Parent Holding Company or
         Controlling Person.
	 Not Applicable
   	


Item 8.  Identification and Classification of Members of the Group.
	 Not Applicable
         


Item 9.  Notice of Dissolution of Group
	 Not Applicable
         


Item 10. Certification

         By signing below I certify that, to the best of my knowledge and
         belief, the securities referred to above were not acquired and are not
         held for the purpose of or with the effect of changing or influencing
         the control of the issuer of the securities and were not acquired and
         are not held in connection with or as a participant in any transaction
         having that purpose or effect.


CUSIP NO.  875372203           	  SCHEDULE 13G


                                   SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief, the
undersigned certify that the information set forth in this statement is true,
complete and correct.


Dated: February 14, 2018


Alyeska Investment Group, L.P.

By: /s/ Jason Bragg
    -------------------------------    
    Name: Jason Bragg   
    Title: Chief Financial Officer and Chief Compliance Officer   


Alyeska Fund GP, LLC

By: /s/ Jason Bragg
    -------------------------------    
    Name:  Jason Bragg   
    Title: Chief Financial Officer and Chief Compliance Officer


Alyeska Fund 2 GP, LLC

By: /s/ Jason Bragg
    -------------------------------    
    Name:  Jason Bragg   
    Title: Chief Financial Officer and Chief Compliance Officer


Anand Parekh

By: /s/ Anand Parekh  
    -------------------------------    
    Name: Anand Parekh     
    Individually




CUSIP NO. 875372203            	SCHEDULE 13G               


                                Exhibit A   
				Agreement
                           

The undersigned agree that the statement to which this exhibit is appended is 
filed on behalf of each of them.

Dated:  February 14, 2018


Alyeska Investment Group, L.P.

By: /s/ Jason Bragg
    -------------------------------    
    Name:  Jason Bragg  
    Title: Chief Financial Officer and Chief Compliance Officer       


Alyeska Fund GP, LLC

By: /s/ Jason Bragg
    -------------------------------    
    Name:  Jason Bragg   
    Title: Chief Financial Officer and Chief Compliance Officer    


Alyeska Fund 2 GP, LLC

By: /s/ Jason Bragg
    -------------------------------    
    Name:  Jason Bragg   
    Title: Chief Financial Officer and Chief Compliance Officer


Anand Parekh

By: /s/ Anand Parekh  
    -------------------------------    
    Name: Anand Parekh     
    Individually